TriSalus Life Sciences Q3 2026 net loss attributable to common stockholders narrows 78% to $8.9 million
TLSI•TriSalus Life Sciences’ third-quarter 2026 net loss attributable to common stockholders narrowed 78% year over year to $8.9 million, while revenue rose 11% to $12.9 million. The company revised full-year 2026 revenue guidance to $46 million–$48 million.
1. Quarterly results
TriSalus Life Sciences reported third-quarter 2026 revenue of $12.9 million, up 11% year over year, driven primarily by higher TriNav unit sales. Net loss attributable to common stockholders narrowed 78% to $8.9 million.
2. Product and reimbursement
The FDA cleared TriNav Advance, enabling pressure-enabled drug delivery to small distal vessels through physicians’ chosen microcatheters. Expanded Medicare reimbursement for pressure-enabled drug delivery procedures takes effect January 1, 2027, including national payment in office-based labs.
3. 2026 guidance
TriSalus revised its full-year 2026 revenue guidance to $46 million–$48 million.
